COLL - Collegium Pharmaceutical, Inc.
About Collegium Pharmaceutical, Inc. (https://www.collegiumpharma.com)
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Vikram Karnani | President, Chief Executive Officer & Director | 1975 | $1,715,846 USD |
| Colleen Tupper | Executive Vice President & Chief Financial Officer | 1976 | $1,030,569 USD |
| Scott Dreyer | Executive Vice President & Chief Commercial Officer | 1972 | $880,739 USD |
| Thomas Smith FAAFP | Executive Vice President & Chief Medical Officer | 1961 | $825,694 USD |
| David Dieter | Executive Vice President, General Counsel & Corporate Secretary | 1964 | $782,283 USD |
| Dean J. Patras | Chief People Officer | – | – |
| Ian Karp | Head of Investor Relations | – | – |
| Jane Gonnerman | Executive Vice President of Strategy & Corporate Development | – | – |
| Jessica Cotrone | Senior Vice President of Communications & Corporate Affairs | – | – |
| Scott Sudduth | EVP & Head of Technical Operations | – | – |